Advanced nanomaterials as sample technique for bio-analysis
N Sun, H Yu, H Wu, X Shen, C Deng - TrAC Trends in Analytical Chemistry, 2021 - Elsevier
The biological compositions including cells, proteins/peptides, nucleic acids, extracellular
vesicles (EVs) and metabolites are no doubt closely related to almost all physiological and …
vesicles (EVs) and metabolites are no doubt closely related to almost all physiological and …
Dormant cancer cells: programmed quiescence, senescence, or both?
Metastasis is the overwhelming driver of cancer mortality, accounting for the majority of
cancer deaths. Many patients present with metastatic relapse years after eradication of the …
cancer deaths. Many patients present with metastatic relapse years after eradication of the …
Serum exosome microRNA as a minimally-invasive early biomarker of AML
NI Hornick, J Huan, B Doron, NA Goloviznina… - Scientific reports, 2015 - nature.com
Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia
(AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely …
(AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely …
State-of-the-art nanotechnologies for the detection, recovery, analysis and elimination of liquid biopsy components in cancer
M Zhao, D Mi, BE Ferdows, Y Li, R Wang, J Li, D Patel… - Nano Today, 2022 - Elsevier
Liquid biopsy allows for the quick and noninvasive detection of tumor-associated
components. Various liquid biopsy components, which include circulating tumor cells, tumor …
components. Various liquid biopsy components, which include circulating tumor cells, tumor …
Advances in circulating tumor DNA analysis
The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might
revolutionize cancer care with respect to early detection, identification of minimal residual …
revolutionize cancer care with respect to early detection, identification of minimal residual …
Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer
X Huang, P Gao, Y Song, J Sun, X Chen, J Zhao, H Xu… - BMC cancer, 2015 - Springer
Background The prognostic value of circulating tumor cells (CTCs) detected with the
CellSearch System in patients with colorectal cancer (CRC) is controversial. The aim of our …
CellSearch System in patients with colorectal cancer (CRC) is controversial. The aim of our …
Cell‐free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer
KLG Spindler, AL Appelt, N Pallisgaard… - … Journal of Cancer, 2014 - Wiley Online Library
The purpose was to investigate total cell‐free DNA (cfDNA) in colorectal cancer (CRC)
patients during treatment with second‐line chemotherapy and in healthy controls and …
patients during treatment with second‐line chemotherapy and in healthy controls and …
Exploring the clinical utility of pancreatic cancer circulating tumor cells
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type,
characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited …
characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited …
Translational significance for tumor metastasis of tumor-associated macrophages and epithelial–mesenchymal transition
W Song, R Mazzieri, T Yang, GC Gobe - Frontiers in immunology, 2017 - frontiersin.org
The tumor microenvironment determines development and progression of many cancers.
Epithelial–mesenchymal transition (EMT) is fundamental to tumor progression and …
Epithelial–mesenchymal transition (EMT) is fundamental to tumor progression and …
Cell‐free DNA in metastatic colorectal cancer: a systematic review and meta‐analysis
KLG Spindler, AK Boysen, N Pallisgård… - The …, 2017 - academic.oup.com
Background Circulating DNA can be detected and quantified in the blood of cancer patients
and used for detection of tumor‐specific genetic alterations. The clinical utility has been …
and used for detection of tumor‐specific genetic alterations. The clinical utility has been …